Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice
A central argument about treatment sequencing is advanced: because CLDN18.2 expression declines progressively under therapeutic pressure, continuous target-plus-chemotherapy acts on an eroding antigen substrate, for patients with high, homogeneous baseline expression, an early intensive induction followed by CLDN18.2-d...